FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 17, 2020 Category: Drugs & Pharmacology Source Type: news

New analysis method for predicting the risks and effects of immunotherapy
(Uppsala University) In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news

New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma
Basel, 07 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the pivotal phase Ib/II GO29365 study, including data from a single-arm extension cohort of 106 additional patients, which show the benefit of Polivy ® (polatuzumab vedotin) plus bendamustine and MabThera®/Rituxan® (rituximab) (BR) in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not eligible for stem cell transplant. Updated data from the randomised cohort (n=80) show that with longer follow-up (48.9 months) a complete response (CR) rate of 42.5% (n=17/40) was maintained ...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news

New follow-up phase III data reinforce the long-term benefit of Roche ’s Hemlibra for people with haemophilia A
Basel, 7 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra ® (emicizumab).[1]These data, from adults, adolescents and children with haemophilia A with and without factor VIII inhibitors, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 5-8 December 2020.“The long-term benefit of Hemlibra, with a consistent safety profile and durably effect...
Source: Roche Media News - December 7, 2020 Category: Pharmaceuticals Source Type: news

New follow-up phase III data reinforce the long-term benefit of Roche ’s Hemlibra for people with haemophilia A
Basel, 7 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra ® (emicizumab).[1]These data, from adults, adolescents and children with haemophilia A with and without factor VIII inhibitors, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 5-8 December 2020.“The long-term benefit of Hemlibra, with a consistent safety profile and durably effect...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia
             Basel, 5 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta ®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). Data were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday 5 December 2020.“...
Source: Roche Media News - December 5, 2020 Category: Pharmaceuticals Source Type: news

Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia
             Basel, 5 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta ®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). Data were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday 5 December 2020.“...
Source: Roche Investor Update - December 5, 2020 Category: Pharmaceuticals Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Xolair ® (omalizumab) for adults with nasal polyps
             Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this ap...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news

Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
SAN FRANCISCO and SUZHOU, China, Oct. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... Biopharmaceuticals, Oncology, Regulatory Innovent Biologics, Eli Lilly, HALPRYZA, rituximab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 9, 2020 Category: Pharmaceuticals Source Type: news

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Increased Risk of Severe COVID With Anti-B-Cell MS Drugs? Increased Risk of Severe COVID With Anti-B-Cell MS Drugs?
Concerns raised over an increased risk of severe COVID-19 outcomes in MS patients on anti-CD20 B-cell depleting drugs such as ocrelizumab and rituximab following presentation of new data.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 29, 2020 Category: Pathology Tags: Neurology & Neurosurgery News Source Type: news

Late-Onset Neutropenia Common in Patients on Rituximab Late-Onset Neutropenia Common in Patients on Rituximab
"Even though most [cases] are incidental and can be self-limiting, some can be severe and associated with sepsis."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Lower Rituximab Dose as Effective, Safer in MS Lower Rituximab Dose as Effective, Safer in MS
Further data suggest that a lower dose of rituximab may offer similar effectiveness with a better safety profile than a higher dose commonly used.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 18, 2020 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Disseminated Enterovirus Infection With Rituximab/Ibrutinib Disseminated Enterovirus Infection With Rituximab/Ibrutinib
This case underscores the risk for severe and potentially life-threatening immune-related side effects with combined therapy with rituximab and ibrutinib.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab In MS, Serious AEs More Common in Rituximab vs Ocrelizumab
Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 11, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Lowering Rituximab Dose in Patients With MS Safe, Effective Lowering Rituximab Dose in Patients With MS Safe, Effective
A new study has found that reducing rituximab dosage from 1,000 mg every 6 months to 500 mg every 6 months is a safe and stable choice for patients with multiple sclerosis.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 10, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

RA Infection Risk With Abatacept, Rituximab and Tocilizumab RA Infection Risk With Abatacept, Rituximab and Tocilizumab
How common are infections among rheumatoid arthritis patients receiving treatment with these non-TNF-inhibitors?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Binding mechanisms of therapeutic antibodies to human CD20
Monoclonal antibodies (mAbs) targeting human antigen CD20 (cluster of differentiation 20) constitute important immunotherapies for the treatment of B cell malignancies and autoimmune diseases. Type I and II therapeutic mAbs differ in B cell binding properties and cytotoxic effects, reflecting differential interaction mechanisms with CD20. Here we present 3.7- to 4.7-angstrom cryo–electron microscopy structures of full-length CD20 in complexes with prototypical type I rituximab and ofatumumab and type II obinutuzumab. The structures and binding thermodynamics demonstrate that upon binding to CD20, type II mAbs form te...
Source: ScienceNOW - August 12, 2020 Category: Science Authors: Kumar, A., Planchais, C., Fronzes, R., Mouquet, H., Reyes, N. Tags: Biochemistry, Medicine, Diseases r-articles Source Type: news

Cladribine With Concurrent or Delayed Rituximab in HCL Cladribine With Concurrent or Delayed Rituximab in HCL
Could the addition of rituximab to cladribine treatment help clear minimal residual disease in patients with hairy cell leukemia?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Isolated IgG4-Related Hypophysitis Treated With Rituximab Isolated IgG4-Related Hypophysitis Treated With Rituximab
Is rituximab a safe and effective treatment option for IgG4-related hypophysitis?Journal of the Endocrine Society (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 30, 2020 Category: Intensive Care Tags: Diabetes & Endocrinology Journal Article Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Roche Pharma India expands partnership with Cipla for key oncology medicines
Roche Pharma India has signed a "distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distribution of its trademark oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin) and rituximab (Ristova) in India," the company said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 17, 2020 Category: Pharmaceuticals Source Type: news

Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
THURSDAY, June 4, 2020 -- For children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma, rituximab added to standard lymphomes malins B (LMB) chemotherapy prolongs event-free survival, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2020 Category: Pharmaceuticals Source Type: news

Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

Long-Term Rituximab May Aid in Antibody-Associated Vasculitis
TUESDAY, June 2, 2020 -- For patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 2, 2020 Category: Pharmaceuticals Source Type: news

Rituximab Promising in New-Onset Myasthenia Gravis Rituximab Promising in New-Onset Myasthenia Gravis
New research suggests rituximab is safer and more effective than immunosuppressants for myasthenia gravis, especially in new-onset disease.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 11, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Rituximab Offers No Extra Benefit to Induction Chemo in ALL Rituximab Offers No Extra Benefit to Induction Chemo in ALL
Patients with B-precursor acute lymphoblastic lymphoma may not benefit from adding rituximab to standard induction chemotherapy, suggests UK trial data that also identified novel genetic risk factors.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

E1912 trial leads to FDA approval of ibrutinib-rituximab combo for untreated CLL
(ECOG-ACRIN Cancer Research Group) Patients aged 70 or younger with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma have a new treatment option -- a combination of the targeted agent ibrutinib with the immunologic agent rituximab. The FDA has approved the combination based on data from E1912, a phase 3 trial that showed this combination provides better leukemia control, prolongs life, and has fewer side effects compared to standard care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2020 Category: Cancer & Oncology Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion av...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Ibrutinib Plus Rituximab Combo for CLL FDA Approves Ibrutinib Plus Rituximab Combo for CLL
This combination of targeted agents showed better progression-free survival than a standard chemoimmunotherapy regimen in patients with newly diagnosed chronic lymphocytic leukemia.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s mi...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Ibrutinib Combined with Rituximab for Patients with CLL/SLL
The FDA approved ibrutinib in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 22, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Imbruvica (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
NORTH CHICAGO, Ill., April 21, 2020– AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of Imbruvica® (ibrutinib) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 21, 2020 Category: Drugs & Pharmacology Source Type: news

Rituximab for Maintenance of Remission in ANCA Vasculitis Rituximab for Maintenance of Remission in ANCA Vasculitis
This article provides a summary of new guidelines regarding the use of rituximab as a treatment option in remission maintenance of ANCA-associated vasculitis.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Russian antitumor drugs first time registered in Europe
(BIOCAD) Two BIOCAD products, Acellbia (INN: rituximab) and Herticad (INN: trastuzumab), received the first European registration certificate in Bosnia and Herzegovina. Registration was received with the support of ICM d.o.o partner and is valid for 5 years. The first deliveries shall start in June 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2020 Category: Cancer & Oncology Source Type: news

Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application.  Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain.   As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn's...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news

Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application.  Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain.   As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn's...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news

Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application.  Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain.   As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn's...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news

Relapse With Rituximab More Common in Severe Pemphigus Relapse With Rituximab More Common in Severe Pemphigus
Pemphigus patients with severe disease and those with persistent anti-desmoglein (DSG) antibodies three months after starting treatment with rituximab are more prone to relapse while on the drug, according to a new post hoc analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 25, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels
FDA approves Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children ages 2 and older in combination with steroid hormones. It is the first approved treatment for children with these rare vasculitis diseases. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Investor Update - March 23, 2020 Category: Pharmaceuticals Source Type: news